Infusion Pump Telemetry Patents: Top Companies & Filing Trends 2026
A data-backed view of infusion pump wireless telemetry patents: who leads filing, how the technology mix breaks down across IPC classes, and where filing growth is heading through 2026.
Filing growth = 2021 (1 records) → 2024 (8); 2024 is the last year we treat as complete. Top-5 share = the 5 largest assignees ÷ all 375 records in scope (CR5), not the ranked leaders only.
What this landscape covers
Infusion pump wireless telemetry sits at the intersection of drug-delivery hardware and connected-device software: pumps that report status, adjust dosing, or accept remote commands over a wireless link. The scope here pulls 375 published records filed or published between 2015 and the 2026 data cut-off, screened against IPC classes spanning body-fluid devices, digital processing, electrotherapy and wireless transmission. That IPC spread is itself informative — this is not a narrow radio-protocol niche, it is a cross-disciplinary claim space where pump mechanics, sensor data and communications law each contribute prior art.
Because publication lags filing by roughly eighteen months, the most recent one to two years in any trend chart will always look thinner than they eventually turn out to be. The analysis below treats 2024 as the last year that can be read as materially complete, and reads 2025 and 2026 as still filling in rather than as a slowdown.
Filing trend and technology composition
Two views of the same 375-record dataset: how filing volume has moved year over year, and which IPC subclasses carry the claim weight.
A sharp rise off a low base, then a partial recent picture
Annual filings sat near zero through the late 2010s, climbed to a peak of 18 in 2020, and — reading only complete years — rose from 1 filing in 2021 to 8 in 2024, a +700% increase over that three-year span. 2025 and 2026 show fewer records only because publication has not caught up with filing yet.
Publication lags filing by roughly 18 months, so 2025 onwards are still filling in. Growth rates on this page therefore end at 2024; running them to the last bar would understate the field.
A61M anchors the field; digital and diagnostic classes layer on top
A61M (devices for body fluids) appears on 68.8% of the 375 records, the highest of any subclass, with G06F (digital data processing) at 46.4% and A61B (diagnosis & surgery) at 45.6% close behind. A61N (electrotherapy) at 37.1% and G16H (healthcare informatics) at 35.5% show how much of this space is drafted as combined hardware-plus-software claims. H04L (digital information transmission), at 5.1%, is comparatively thin given that telemetry is the defining feature of the search — a signal that most applicants claim the pump and its data behaviour together rather than the radio link on its own.
Shares are the percentage of the 375 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Infusion Pump Wireless Telemetry Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about infusion pump wireless telemetry patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited prior art and a representative recent filing
US11957869B2 — Dual mode geofencing for medical devices (CareFusion 303, 2024-04-16)
The claimed pump combines a wireless transceiver, pump motor, location sensor, battery and processor in one housing. It monitors a geofence parameter through the location sensor, detects a change in the pump's location relative to that parameter, identifies which operation mode is tied to the geofence, and automatically switches modes when the location changes.Location-triggered mode switching layered onto a standard telemetry-equipped pump architecture.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5569186A | Closed loop infusion pump system with removable glucose sensor | 2,310 |
| 2 | US5665065A | Medication infusion device with blood glucose data input | 2,103 |
| 3 | US4373527A | Implantable programmable medication infusion system | 1,937 |
| 4 | US6694191B2 | Ambulatory medical apparatus and method having telemetry modifiable control software | 1,762 |
| 5 | US20040068224A1 | Electroactive polymer actuated medication infusion pumps | 1,723 |
| 6 | US6810290B2 | Ambulatory medical apparatus with hand held communication device | 1,573 |
| 7 | US6740075B2 | Ambulatory medical apparatus with hand held communication device | 1,564 |
| 8 | US6585644B2 | Ambulatory medical apparatus and method using a telemetry system with predefined reception listening periods | 1,525 |
| 9 | US6648821B2 | Microprocessor controlled ambulatory medical apparatus with hand held communication device | 1,505 |
| 10 | US6562001B2 | Microprocessor controlled ambulatory medical apparatus with hand held communication device | 1,468 |
Citation counts reflect influence inside the searched corpus and skew toward older records; they are not a measure of current commercial weight.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the concentration and citation data indicate
Three figures worth sitting with before deciding where to file or who to watch.
The field is led, not fragmented
The five leading assignees account for 51.2% of all 375 records in scope, and the ranked leaders' top ten hold 65.9%. A field this concentrated at the top, with a long tail of single- and few-filing entrants behind it, means new entrants are more likely to find open ground in combination claims than in the core pump-plus-telemetry architecture itself.
Recent growth is real, not an artifact
Annual filings rose from 1 in 2021 to 8 in 2024 — a +700% increase over that three-year span, using only years complete enough to compare fairly. That is a meaningful acceleration off a low base rather than a mature, flattening curve.
Foundational patents still anchor freedom-to-operate review
The most-cited record in this dataset, on closed-loop infusion with glucose sensing, carries 2,310 citations, and the next four most-cited records are all from the 1990s–2000s. Any new filing in closed-loop dosing or telemetry-modifiable control software should expect examiners to cite this cluster regardless of filing date.
Filing strategy is US-centred with a PCT hedge
United States filings (162) outnumber the next receiving office, EPO (60), by more than 2.5 times, with WIPO/PCT filings (53) suggesting many applicants keep international options open before committing to national phase elsewhere.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to infusion pump wireless telemetry patent landscape, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| MEDICAL RESEARCH GROUP INC | MINIMED INC | 8 |
| Medtronic MiniMed | MOBERG SHELDON B | 3 |
| Medtronic MiniMed | MEHTA KAEZAD J | 3 |
| Medtronic MiniMed | TOLLE CHARLES VALLET | 2 |
| Medtronic MiniMed | SANDERS JEFF B | 2 |
| Medtronic MiniMed | SAIDARA FRANK | 2 |
| Medtronic MiniMed | NIELSEN EDWARD S | 2 |
| Medtronic MiniMed | MUELLER JOHN C JR | 2 |
Ten co-assignee pairs appear in the dataset. The strongest, an 8-record pairing between two related medical-device entities, points to a single R&D group filing jointly rather than to cross-company technology licensing.
Where to take this analysis
The dataset points to specific follow-up work depending on what you are trying to decide.
Freedom-to-operate on closed-loop dosing
The five most-cited records all touch closed-loop infusion, glucose-sensing input, or telemetry-modifiable control software. Any filing in that cluster needs a claim chart against those five before drafting.
Run a claim comparison in EurekaMap the under-claimed combination space
H04L sits at only 5.1% of records despite telemetry being the search's defining feature, suggesting radio-link claims are usually bundled into pump claims rather than filed standalone.
Explore white space in EurekaTrack the leading assignees' recent filings
With the top five holding 51.2% of all 375 records, a standing watch on their newest publications will surface architecture shifts before they show up in citation data.
Set up assignee monitoring in EurekaCommon questions about this landscape
The dataset's assignee ranking is led by a single company with 103 records, well ahead of the rest of the field. The top five assignees combined hold 51.2% of all 375 records in scope, and the top ten hold 65.9%, so the field is concentrated among a small group of established infusion-pump manufacturers rather than spread evenly. Behind that concentrated top tier sits a long tail of companies with only one or a few filings each, which is where most new entrants land.
Using only years complete enough to compare fairly, annual filings rose from 1 in 2021 to 8 in 2024 — a +700% increase over that three-year span. The dataset's overall peak so far was 18 filings in 2020. Figures for 2025 and 2026 look lower, but that reflects the roughly 18-month lag between filing and publication rather than an actual slowdown, so those two years should not be read as a decline.
A61M, the IPC class for devices handling body fluids, appears on 68.8% of the 375 records and is the clear backbone of the field. Digital data processing (G06F, 46.4%) and diagnosis-and-surgery classes (A61B, 45.6%) are close behind, showing that most filings combine pump hardware with software or diagnostic logic rather than claiming either alone. Healthcare informatics (G16H, 35.5%) and electrotherapy (A61N, 37.1%) round out a genuinely cross-disciplinary claim landscape.
The pure communications class H04L sits at just 5.1% of the 375 records despite telemetry being central to the search criteria, which suggests most existing claims bundle the radio link into broader pump-and-software claims rather than protecting transmission methods on their own. That gap, combined with a long tail of single-filing entrants behind a concentrated top group, points to standalone communications-layer claims and novel combination architectures as the more open filing routes. Any white-space assessment should still be checked against the most-cited foundational patents before drafting.
Start with the five most-cited records in this dataset, led by a closed-loop infusion patent with 2,310 citations and a medication-infusion device patent with 2,103 citations. These older, heavily cited filings anchor prior art across closed-loop dosing, glucose-sensing input, and telemetry-modifiable control software, and examiners are likely to cite them regardless of how recent a new application is. A representative recent filing, US11957869B2 on geofence-triggered mode switching, shows how newer claims layer location awareness on top of that established architecture.
Research Infusion Pump Wireless Telemetry Patent Landscape in depth with Eureka
Go past this page: query the whole infusion pump wireless telemetry patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.